scholarly journals Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

Diabetes Care ◽  
2019 ◽  
Vol 42 (6) ◽  
pp. 1075-1080 ◽  
Author(s):  
M. Angelyn Bethel ◽  
Rishi A. Patel ◽  
Vivian P. Thompson ◽  
Peter Merrill ◽  
Shelby D. Reed ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Cardiovascular Event ◽  
Serum Calcitonin ◽  
Medullary Thyroid

scholarly journals Usefulness of preoperative serum calcitonin in patients with nodular thyroid disease without suspicious history or cytology for medullary thyroid carcinoma

2013 ◽  
Vol 57 (4) ◽  
pp. 312-316 ◽  
Author(s):  
Pedro Weslley Rosário ◽  
Gustavo Cancela Penna ◽  
Kamilla Brandão ◽  
Bárbara Érika Souza
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Multiple Endocrine Neoplasia ◽  
Multiple Endocrine Neoplasia Type ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Endocrine Neoplasia ◽  
Preoperative Serum ◽  
History Of

OBJECTIVE: To evaluate the usefulness of preoperative serum calcitonin (sCT) in patients with nodular disease without suspicion of medullary thyroid carcinoma (MTC) in history or cytology. PATIENTS AND METHODS: sCT was measured before thyroidectomy in 494 patients with nodular disease who had no family history of MTC or multiple endocrine neoplasia type 2, and no cytological suspicion of MTC. RESULTS: Basal sCT was < 10 ng/mL in 482 patients and none of them had MTC. One patient with basal sCT > 100 pg/mL had MTC. Among the 11 patients with basal sCT between 10 and 100 pg/mL, MTC was diagnosed in only one. The two patients with MTC were submitted to total thyroidectomy, combined with elective lymph node dissection indicated exclusively based on hypercalcitoninemia, and sCT was undetectable after six months. CONCLUSIONS: Preoperative sCT is useful for the detection of sporadic MTC in patients with nodular disease, even in the absence of suspicious history or cytology.

scholarly journals Serum calcitonin negative Medullary thyroid carcinoma

2006 ◽  
Vol 4 (1) ◽  
Author(s):  
Michael Sand ◽  
Marcos Gelos ◽  
Daniel Sand ◽  
Falk G Bechara ◽  
Gerd Bonhag ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Serum Calcitonin ◽  
Medullary Thyroid

Disappearance Rate of Serum Calcitonin after Total Thyroidectomy for Medullary Thyroid Carcinoma

1994 ◽  
Vol 9 (1) ◽  
pp. 21-24 ◽  
Author(s):  
L. Fugazzola ◽  
A. Pinchera ◽  
F. Luchetti ◽  
P. Iacconi ◽  
P. Miccoli ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Total Thyroidectomy ◽  
Medullary Thyroid Carcinoma ◽  
Half Life ◽  
Slow Component ◽  
General Rule ◽  
Disappearance Rate ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Undetectable Serum

We studied the half-life of serum calcitonin (CT) in patients subjected to total thyroidectomy for medullary thyroid carcinoma (MTC). One patient showed a rapid serum CT component with a half-life of 3 hours and a slow component with a half-life of 30 hours; in another case only the 30-hour component was found. By chromatography of tumor extracts, we found that all the immunoreactive CT had a molecular weight of 3,600. After surgery, normalization of serum CT was achieved within 15 days in 4 patients, at 3 months and at 6 months in 2 other patients, while 1 patient never normalized. Normalization of serum CT after surgery is not an index of definitive cure in MTC, as demonstrated by one patient who relapsed 3 months after normalization of serum CT. However, as a general rule, patients who reach undetectable serum CT levels soon after surgery, are those having the best prognosis.

C-Cell Hyperplasia and Medullary Thyroid Carcinoma in Patients Routinely Screened for Serum Calcitonin

1998 ◽  
Vol 22 (6) ◽  
pp. 722-728 ◽  
Author(s):  
Klaus Kaserer ◽  
Christian Scheuba ◽  
Nikolaus Neuhold ◽  
Andreas Weinhäusel ◽  
Heinrich Vierhapper ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Cell Hyperplasia ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
C Cell Hyperplasia ◽  
C Cell

Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group

2006 ◽  
Vol 24 (11) ◽  
pp. 1705-1711 ◽  
Author(s):  
Jean-François Chatal ◽  
Loïc Campion ◽  
Françoise Kraeber-Bodéré ◽  
Stephane Bardet ◽  
Jean-Philippe Vuillez ◽  
...  
Keyword(s):  
Bone Marrow ◽  
High Risk ◽  
Thyroid Carcinoma ◽  
Carcinoembryonic Antigen ◽  
Medullary Thyroid Carcinoma ◽  
Bone Marrow Involvement ◽  
Prognostic Indicators ◽  
Tumor Spread ◽  
Serum Calcitonin ◽  
Medullary Thyroid

Purpose No effective therapy is currently available for the management of patients with metastatic medullary thyroid carcinoma (MTC). The efficacy of pretargeted radioimmunotherapy (pRAIT) with bispecific monoclonal antibody (BsMAb) and a iodine-131 (131I) –labeled bivalent hapten is evaluated. Patients and Methods Twenty-nine patients with advanced, progressive MTC, as documented by short serum calcitonin doubling times (Ct DTs), received an anti–carcinoembryonic antigen (CEA)/anti–diethylenetriamine pentaacetic acid (DTPA) –indium BsMAb, followed 4 days later by a 131I-labeled bivalent hapten. Overall survival (OS) was compared with 39 contemporaneous untreated MTC patients with comparable prognostic indicators. Results OS was significantly longer in high-risk, treated patients (Ct DT < 2 years) than in high-risk, untreated patients (median OS, 110 v 61 months; P < .030). Forty-seven percent of patients, defined as biologic responders by a more than 100% increase in CtDT, experienced significantly longer survival than nonresponders (median OS, 159 v 109 months; P < .035) and untreated patients (median OS, 159 v 61 months; P < .010). Treated patients with bone/bone-marrow disease had a longer survival than patients without such involvement (10-year OS, 83% v 14%; P < .023). Toxicity was mainly hematologic and related to bone/bone-marrow tumor spread. Conclusion pRAIT against CEA induced long-term disease stabilization and a significantly longer survival in high-risk patients with Ct DTs less than 2 years, compared with similarly high-risk, untreated patients. Ct DT and bone-marrow involvement appear to be prognostic indicators in MTC patients who undergo pRAIT.

Evaluation of surgical results and prediction of prognosis in patients with medullary thyroid carcinoma by analysis of serum calcitonin levels

1988 ◽  
Vol 12 (5) ◽  
pp. 610-615 ◽  
Author(s):  
Akira Miyauchi ◽  
Fumio Matsuzuka ◽  
Kanji Kuma ◽  
Shin -ichiro Takai ◽  
Kembu Nakamoto ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Surgical Results ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Prediction Of Prognosis
Sign in / Sign up

Export Citation Format

Share Document